Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 1/20 | 1.00 |
| ▸ | HTR2A | P28223 | 1/20 | 0.59 |
| ▸ | HTR2C | P28335 | 1/20 | 0.59 |
| ▸ | HTR2B | P41595 | 1/20 | 0.59 |
| ▸ | TUBB1 | Q9H4B7 | 4/20 | 0.58 |
| ▸ | ACHE | P22303 | 1/20 | 0.54 |
| ▸ | TUBB4A | P04350 | 3/20 | 0.53 |
| ▸ | TUBB | P07437 | 3/20 | 0.53 |
| ▸ | TUBA3C | P0DPH7 | 3/20 | 0.53 |
| ▸ | TUBA1B | P68363 | 3/20 | 0.53 |
| ▸ | TUBA4A | P68366 | 3/20 | 0.53 |
| ▸ | TUBB4B | P68371 | 3/20 | 0.53 |
| ▸ | TUBB3 | Q13509 | 3/20 | 0.53 |
| ▸ | TUBB2A | Q13885 | 3/20 | 0.53 |
| ▸ | TUBB8 | Q3ZCM7 | 3/20 | 0.53 |
| ▸ | TUBA3E | Q6PEY2 | 3/20 | 0.53 |
| ▸ | TUBA1A | Q71U36 | 3/20 | 0.53 |
| ▸ | TUBA1C | Q9BQE3 | 3/20 | 0.53 |
| ▸ | TUBB6 | Q9BUF5 | 3/20 | 0.53 |
| ▸ | TUBB2B | Q9BVA1 | 3/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12309883 | 0.87 | PTGS2 (0.76) | PTGS2HTR2AHTR2CHTR2BTUBB1 | |
| SCHEMBL8372028 | 0.85 | PTGS2 (0.73) | PTGS2HTR2AHTR2CHTR2BTUBB1 | |
| SCHEMBL8372053 | 0.85 | PTGS2 (0.73) | PTGS2HTR2AHTR2CHTR2BTUBB1 | |
| SCHEMBL8434037 | 0.85 | PTGS2 (0.73) | PTGS2HTR2AHTR2CHTR2BTUBB1 | |
| SCHEMBL13753908 | 0.85 | PTGS2 (0.73) | PTGS2HTR2AHTR2CHTR2BTUBB1 | |
| SCHEMBL18071824 | 0.84 | PTGS2 (0.72) | PTGS2HTR2AHTR2CHTR2BTUBB1 | |
| SCHEMBL31143713 | 0.84 | PTGS2 (0.72) | PTGS2HTR2AHTR2CHTR2BTUBB1 | |
| SCHEMBL9184918 | 0.83 | TUBB1 (0.73) | PTGS2HTR2AHTR2CHTR2BTUBB1 | |
| SCHEMBL31540294 | 0.82 | PTGS2 (0.69) | PTGS2HTR2AHTR2CHTR2BTUBB1 | |
| SCHEMBL4464142 | 0.82 | HTR2A (0.75) | PTGS2HTR2AHTR2CHTR2BTUBB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 508 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106518750-B | Carbazole amino alcohol compound, preparation method thereof and application of carbazole amino alcohol compound in resisting parasitic diseases | 中国疾病预防控制中心寄生虫病预防控制所 | 2021-06-01 | — | — | CN | claimed |
| US-7749985-B2 | Acyloxyalkyl carbamate prodrugs, methods of synthesis and use | XENOPORT, INC. (US) | 2010-07-06 | — | — | US | claimed |
| EP-1630165-B1 | [1,2,4]TRIAZOLO[1,5-a]PYRIMIDIN-2-YLUREA DERIVATIVE AND USE THEREOF | NIPPON KAYAKU KK (JP) | 2010-03-31 | — | — | EP | claimed |
| US-20090286759-A1 | ACYLOXYALKYL CARBAMATE PRODRUGS, METHODS OF SYNTHESIS AND USE | XENOPORT, INC. (US) | 2009-11-19 | — | — | US | claimed |
| US-7598244-B2 | [1,2,4]triazolo[1,5,a]pyrimidin-2-ylurea derivative and use thereof | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2009-10-06 | — | — | US | claimed |
| US-7585996-B2 | Acyloxyalkyl carbamate prodrugs, methods of synthesis and use | XENOPORT, INC. (US) | 2009-09-08 | — | — | US | claimed |
| US-20080146526-A1 | Acyloxyalkyl carbamate prodrugs, methods of synthesis and use | XENOPORT, INC. | 2008-06-19 | — | — | US | claimed |
| WO-2008033572-A1 | ACYLOXYALKYL CARBAMATE PRODRUGS, METHODS OF SYNTHESIS AND USE | XENOPORT, INC. (US) | 2008-03-20 | — | — | WO | claimed |
| US-20070010515-A1 | [1,2,4] Triazolo [1,5, a] pyrimidin-2-ylurea derivative and use thereof | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2007-01-11 | — | — | US | claimed |
| EP-1630165-A1 | [1,2,4 ]TRIAZOLO [1,5-A]PYRIMIDIN-2-YLUREA DERIVATIVE AND USE THEREOF | Nippon Kayaku Kabushiki Kaisha (JP) | 2006-03-01 | — | — | EP | claimed |
| EP-0543780-A2 | Novel aminoalkanephosphinic acids and their salts | CIBA-GEIGY AG (CH) | 1993-05-26 | — | — | EP | claimed |
| EP-0251194-B1 | USE OF CARBOCYCLIC AND HETEROCYCLIC CONDENSED DIHYDROPYRIDINES FOR THE PREPARATION OF CARDIOPROTECTIVE REMEDIES AND HETEROCYCLIC AND CARBOCYCLIC CONDENSED DIHYDROPYRIDINES AND METHODS AND INTERMEDIATES FOR THEIR PREPARATION | BOEHRINGER INGELHEIM KG (DE) | 1993-03-31 | — | — | EP | claimed |
| WO-1992011010-A1 | NEW 3,4-DIHYDROISOQUINOLINE DERIVATES AND NEW PHARMACEUTICAL USE OF CARBOCYCLICALLY AND HETEROCYCLICALLY ANNULATED DIHYDROPYRIDINES | BOEHRINGER INGELHEIM KG (DE) | 1992-07-09 | — | — | WO | claimed |
| EP-0171217-B1 | FUSED-RING HETEROCYCLIC COMPOUNDS A PROCESS FOR THEIR PRODUCTION AND THEIR PHARMACEUTICAL USE | SANKYO COMPANY LIMITED (JP) | 1989-05-03 | — | — | EP | claimed |
| EP-0251194-A1 | Use of carbocyclic and heterocyclic condensed dihydropyridines for the preparation of cardioprotective remedies and heterocyclic and carbocyclic condensed dihydropyridines and methods and intermediates for their preparation | BOEHRINGER INGELHEIM KG (DE) | 1988-01-07 | — | — | EP | claimed |
| US-4716162-A | BRAIN FUNCTION | SANKYO COMPANY, LIMITED (JP) | 1987-12-29 | — | — | US | claimed |
| US-4584300-A | Platelet anti-aggregative- and calcium antagonistic -1,4-benzothiazin-3-one derivatives, compositions, and methods of use therefor | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 1986-04-22 | — | — | US | claimed |
| EP-0171217-A2 | Fused-ring heterocyclic compounds a process for their production and their pharmaceutical use | SANKYO COMPANY LIMITED (JP) | 1986-02-12 | — | — | EP | claimed |
| EP-0116368-A1 | Benzothiazine derivatives | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 1984-08-22 | — | — | EP | claimed |
| US-4024156-A | Thiophene ethanolamines | AMERICAN HOME PRODUCTS CORPORATION (US) | 1977-05-17 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286759-A1 | ACYLOXYALKYL CARBAMATE PRODRUGS, METHODS OF SYNTHESIS AND USE | APEH, NAPEPLD, AASDHPPT | PTGS2 2620/4885HTR2A 773/4885HTR2C 928/4885 |
| US-20070010515-A1 | [1,2,4] Triazolo [1,5, a] pyrimidin-2-ylurea derivative and use thereof | HLA-C, TPMT, TAP1 | PTGS2 716/4885HTR2A 4137/4885HTR2C 3827/4885 |
| US-20080146526-A1 | Acyloxyalkyl carbamate prodrugs, methods of synthesis and use | APEH, NAPEPLD, AASDHPPT | PTGS2 2620/4885HTR2A 773/4885HTR2C 928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.